Background
Phase 3, open-label, randomized controlled trial (KarMMa-3). N=386 patients with relapsed or refractory multiple myeloma after 2–4 prior lines including a PI, IMiD, and daratumumab. Randomized 2:1 (ide-cel vs standard regimens). The comparator was one of 5 physician-selected standard regimens (DPd, DVd, IRd, Elo-Pd, Dara-Kd).
Interventions and follow up
Arm A: Idecabtagene vicleucel (ide-cel) 150–450 × 10⁶ CAR-T cells IV (after fludarabine/cyclophosphamide lymphodepletion), single infusion; leukapheresis before standard bridging therapy
Arm B: Standard regimen (physician-selected from 5 options: DPd, DVd, IRd, elotuzumab-Pd, or DKd), continuous until progression
Primary endpoint: Progression-free survival (PFS)
mFollow up: 18.6 months
Arm B: Standard regimen (physician-selected from 5 options: DPd, DVd, IRd, elotuzumab-Pd, or DKd), continuous until progression
Primary endpoint: Progression-free survival (PFS)
mFollow up: 18.6 months
Results
mPFS: 13.3 vs 4.4 months, HR 0.49 (95% CI 0.38–0.65), P<.001
ORR: 71% vs 42%
≥CR rate: 39% vs 5%
mOS: Trend favoring ide-cel, not significant at interim (crossover-confounded)
ORR: 71% vs 42%
≥CR rate: 39% vs 5%
mOS: Trend favoring ide-cel, not significant at interim (crossover-confounded)
Adverse events
CRS/neurotoxicity (ide-cel): CRS any grade 88%, grade ≥3 5%; ICANS any grade 15%, grade ≥3 3%
Hematologic (grade ≥3, ide-cel): Neutropenia 78%, anemia 56%, thrombocytopenia 54%
Infections: Grade ≥3 24% (ide-cel); treatment-related deaths <1%
Hematologic (grade ≥3, ide-cel): Neutropenia 78%, anemia 56%, thrombocytopenia 54%
Infections: Grade ≥3 24% (ide-cel); treatment-related deaths <1%
Conclusions
Ide-cel significantly improved PFS (HR 0.49, mPFS 13.3 vs 4.4 months) and response depth vs standard triplet regimens in 2–4 line triple-class-exposed RRMM, supporting earlier use of BCMA CAR-T therapy in the myeloma treatment algorithm.
Key Limitations
Open-label design and heterogeneous physician-selected comparator regimens complicate interpretation. The standard-arm mPFS of 4.4 months was notably short, and extensive crossover to ide-cel at progression confounded the OS analysis. Manufacturing logistics and bridging-therapy needs mean not all randomized patients received the assigned CAR-T. Some prolonged cytopenias and infections persist beyond the acute period.
Clinical Context
KarMMa-3 supported the FDA's April 2024 label expansion of ide-cel (Abecma) to RRMM after ≥2 prior lines including an IMiD, PI, and anti-CD38 antibody. It established BCMA CAR-T as a randomized-evidence option in earlier relapse, paralleling CARTITUDE-4 for cilta-cel. ESMO-MCBS reflects substantial PFS benefit.